Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexavalent Recombinant Norovirus Vaccine (Hansenula) Phase II Trial in 6 Months–17 Years
CTR20254919Phase 2Active
- Sponsor
- Grand Sevaxin
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of hexavalent recombinant norovirus vaccine in Noroviral gastroenteritis, sponsored by Grand Sevaxin. Started Dec 2025; status: active.
02
Drugs
hexavalent recombinant norovirus vaccine
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on CTR20254919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254919.